Clinical Trials in Italy / NCT07494578
Active, not recruiting
Observational
Observational Study Regarding the Combination of Fluoropyrimidine and Bevacizumab in Patients With mCRC
NCT07494578 · tracked via the Priya Life Science Italy tracker
Condition(s) studied
Colon Cancer Metastatic
Investigational drug(s) / intervention(s)
Fluoropyrimidine: Treatment with fluoropyrimidines and bevacizumab
Study summary
This study will enroll patients with metastatic colorectal cancer treated with the combination of Trifluridine/Tipiracile and Bevacizumab across 15 italian centers.
Eligibility
Inclusion Criteria:
* Age ≥18 years;
* ECOG PS 0-2;
* Histologic diagnosis of colorectal cancer;
* Treatment with fluoropyrimidine plus bevacizumab.
Exclusion Criteria:
* ECOG PS ≥3;
* Absence of histologic diagnosis.
Primary outcome measure(s)
- Overall Survival — up to 30 months from the date of treatments' start
Time from start of the treatment to death from any cause up to 30 months from the date of treatments' start. - Progression-free survival — up to 30 months from the date of treatments' start
time from the start of the treatment to disease progression or death from any cause, whichever occurred first, up to 30 months from the date of treatments' start.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Policlinico Universitario Agostino Gemelli | Rome | Lazio |
More Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials in Italy
Modular Neurological Examination for Early Risk Detection
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07494578 on ClinicalTrials.gov ↗ ← All trials in Italy